Validation Data Gallery
|Positive WB detected in
|mouse small intestine tissue, human placenta tissue
|Positive IHC detected in
|human kidney tissue, human cervical cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)
|WB : 1:500-1:2400
|IHC : 1:20-1:200
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
12166-1-AP targets Dysadherin in WB, IHC, ELISA applications and shows reactivity with human, mouse samples.
|human, mouse, rat
|Host / Isotype
|Rabbit / IgG
|Dysadherin fusion protein Ag2808
|FXYD domain containing ion transport regulator 5
|Calculated molecular weight
|178 aa, 19 kDa
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
Dysadherin, also known as FXYD5 (FXYD domain containing ion transport regulator 5), is a cancer-associated cell membrane glycoprotein which belongs to the FXYD family. The FXYD family, which contains seven members, are tissue specific regulators of the Na,K-ATPase. Dysadherin is involved in down-regulation of E-cadherin, which plays important roles in tumor development and metastasis. It is present in spleen, lung, skeletal muscle, and testis. Increased expression of dysadherin has been associated with increased cell motility and metastatic potential.
Int J Oncol
A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer.
FXYD domain containing ion transport regulator 5 (FXYD5) silencing promotes cell viability and alleviates inflammatory response in cerulein-induced AR42J cells by blocking JAK2/STAT3 signaling pathway.
Generation of the novel anti-FXYD5 monoclonal antibody and its application to the diagnosis of pancreatic and lung cancer
miR-1180 Targets FXYD5 to Regulate Pancreatic Cancer Cells Migration and Invasion